Come attuare il follow-up in rapporto alla categoria di rischio.

Translated title of the contribution: [How to apply follow-up in relation to risk group].

Vittorino Montanaro, Antonio Di Girolamo, Matteo Ferro, Vincenzo Altieri

Research output: Contribution to journalArticle

Abstract

The term 'Non-muscle invasive bladder cancer' identifies a heterogeneous disease due to different natural history of its various appearances. T1 stage represents a non-predictable population, which might respond to non-operative treatment strategies or to the need of a more aggressive treatment, in order to avoid the progression to invasive, and possibly to metastatic stages. In the first year following transurethral resection of bladder (TURB), tumor recurrence is seen in up to 45% of the population; of this, 15% may progress to muscle invasive or metastatic disease, or both. In order to control the recurrence and progression and identify invasive tumors at the earliest possible stage, it is strongly necessary to define individual patient risk assessment follow-up. To obtain exact staging, besides a proper transurethral resection of bladder, a restaging transurethral resection of bladder should be performed in T1 patients. Data from literature support the immediate postoperative intravesical instillation of different chemotherapeutic agents in low-risk patients. Multifocal papillary lesions might require a more intensive adjuvant regimen, whereas intravesical immunotherapy using Bacillus Calmette-Guérin is recommended in patients at high risk of progression. Early cystectomy should be considered in patients with recurrent T1 tumors or refractory carcinoma in situ to avoid unfavorable tumor progression.

Original languageItalian
Pages (from-to)42-47
Number of pages6
JournalUrologia
Volume80 Suppl 21
Publication statusPublished - 2013

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Intravesical Administration
Recurrence
Neoplasms
Cystectomy
Carcinoma in Situ
Natural History
Immunotherapy
Bacillus
Population
Muscles
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Montanaro, V., Di Girolamo, A., Ferro, M., & Altieri, V. (2013). Come attuare il follow-up in rapporto alla categoria di rischio. Urologia, 80 Suppl 21, 42-47.

Come attuare il follow-up in rapporto alla categoria di rischio. / Montanaro, Vittorino; Di Girolamo, Antonio; Ferro, Matteo; Altieri, Vincenzo.

In: Urologia, Vol. 80 Suppl 21, 2013, p. 42-47.

Research output: Contribution to journalArticle

Montanaro, V, Di Girolamo, A, Ferro, M & Altieri, V 2013, 'Come attuare il follow-up in rapporto alla categoria di rischio.', Urologia, vol. 80 Suppl 21, pp. 42-47.
Montanaro V, Di Girolamo A, Ferro M, Altieri V. Come attuare il follow-up in rapporto alla categoria di rischio. Urologia. 2013;80 Suppl 21:42-47.
Montanaro, Vittorino ; Di Girolamo, Antonio ; Ferro, Matteo ; Altieri, Vincenzo. / Come attuare il follow-up in rapporto alla categoria di rischio. In: Urologia. 2013 ; Vol. 80 Suppl 21. pp. 42-47.
@article{f2849fc72a0d4a98bd5006d7ea5e6f6e,
title = "Come attuare il follow-up in rapporto alla categoria di rischio.",
abstract = "The term 'Non-muscle invasive bladder cancer' identifies a heterogeneous disease due to different natural history of its various appearances. T1 stage represents a non-predictable population, which might respond to non-operative treatment strategies or to the need of a more aggressive treatment, in order to avoid the progression to invasive, and possibly to metastatic stages. In the first year following transurethral resection of bladder (TURB), tumor recurrence is seen in up to 45{\%} of the population; of this, 15{\%} may progress to muscle invasive or metastatic disease, or both. In order to control the recurrence and progression and identify invasive tumors at the earliest possible stage, it is strongly necessary to define individual patient risk assessment follow-up. To obtain exact staging, besides a proper transurethral resection of bladder, a restaging transurethral resection of bladder should be performed in T1 patients. Data from literature support the immediate postoperative intravesical instillation of different chemotherapeutic agents in low-risk patients. Multifocal papillary lesions might require a more intensive adjuvant regimen, whereas intravesical immunotherapy using Bacillus Calmette-Gu{\'e}rin is recommended in patients at high risk of progression. Early cystectomy should be considered in patients with recurrent T1 tumors or refractory carcinoma in situ to avoid unfavorable tumor progression.",
author = "Vittorino Montanaro and {Di Girolamo}, Antonio and Matteo Ferro and Vincenzo Altieri",
year = "2013",
language = "Italian",
volume = "80 Suppl 21",
pages = "42--47",
journal = "Urologia",
issn = "0391-5603",
publisher = "Wichtig Publishing",

}

TY - JOUR

T1 - Come attuare il follow-up in rapporto alla categoria di rischio.

AU - Montanaro, Vittorino

AU - Di Girolamo, Antonio

AU - Ferro, Matteo

AU - Altieri, Vincenzo

PY - 2013

Y1 - 2013

N2 - The term 'Non-muscle invasive bladder cancer' identifies a heterogeneous disease due to different natural history of its various appearances. T1 stage represents a non-predictable population, which might respond to non-operative treatment strategies or to the need of a more aggressive treatment, in order to avoid the progression to invasive, and possibly to metastatic stages. In the first year following transurethral resection of bladder (TURB), tumor recurrence is seen in up to 45% of the population; of this, 15% may progress to muscle invasive or metastatic disease, or both. In order to control the recurrence and progression and identify invasive tumors at the earliest possible stage, it is strongly necessary to define individual patient risk assessment follow-up. To obtain exact staging, besides a proper transurethral resection of bladder, a restaging transurethral resection of bladder should be performed in T1 patients. Data from literature support the immediate postoperative intravesical instillation of different chemotherapeutic agents in low-risk patients. Multifocal papillary lesions might require a more intensive adjuvant regimen, whereas intravesical immunotherapy using Bacillus Calmette-Guérin is recommended in patients at high risk of progression. Early cystectomy should be considered in patients with recurrent T1 tumors or refractory carcinoma in situ to avoid unfavorable tumor progression.

AB - The term 'Non-muscle invasive bladder cancer' identifies a heterogeneous disease due to different natural history of its various appearances. T1 stage represents a non-predictable population, which might respond to non-operative treatment strategies or to the need of a more aggressive treatment, in order to avoid the progression to invasive, and possibly to metastatic stages. In the first year following transurethral resection of bladder (TURB), tumor recurrence is seen in up to 45% of the population; of this, 15% may progress to muscle invasive or metastatic disease, or both. In order to control the recurrence and progression and identify invasive tumors at the earliest possible stage, it is strongly necessary to define individual patient risk assessment follow-up. To obtain exact staging, besides a proper transurethral resection of bladder, a restaging transurethral resection of bladder should be performed in T1 patients. Data from literature support the immediate postoperative intravesical instillation of different chemotherapeutic agents in low-risk patients. Multifocal papillary lesions might require a more intensive adjuvant regimen, whereas intravesical immunotherapy using Bacillus Calmette-Guérin is recommended in patients at high risk of progression. Early cystectomy should be considered in patients with recurrent T1 tumors or refractory carcinoma in situ to avoid unfavorable tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=84882262732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882262732&partnerID=8YFLogxK

M3 - Articolo

C2 - 23559135

AN - SCOPUS:84882262732

VL - 80 Suppl 21

SP - 42

EP - 47

JO - Urologia

JF - Urologia

SN - 0391-5603

ER -